1. Home
  2. PHI vs KNSA Comparison

PHI vs KNSA Comparison

Compare PHI & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PHI

PLDT Inc. Sponsored ADR

HOLD

Current Price

$17.91

Market Cap

4.9B

ML Signal

HOLD

Logo Kiniksa Pharmaceuticals Ltd.

KNSA

Kiniksa Pharmaceuticals Ltd.

HOLD

Current Price

$63.89

Market Cap

4.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PHI
KNSA
Founded
1928
2015
Country
Philippines
United Kingdom
Employees
14420
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.9B
4.9B
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
PHI
KNSA
Price
$17.91
$63.89
Analyst Decision
Hold
Strong Buy
Analyst Count
1
7
Target Price
N/A
$60.86
AVG Volume (30 Days)
237.3K
890.0K
Earning Date
05-12-2026
04-28-2026
Dividend Yield
5.88%
N/A
EPS Growth
N/A
225.00
EPS
N/A
0.27
Revenue
N/A
$677,564,000.00
Revenue This Year
$4.16
$37.48
Revenue Next Year
$2.56
$17.87
P/E Ratio
$10.44
$238.85
Revenue Growth
N/A
60.09
52 Week Low
$17.05
$26.27
52 Week High
$24.51
$64.81

Technical Indicators

Market Signals
Indicator
PHI
KNSA
Relative Strength Index (RSI) 46.67 72.76
Support Level $17.05 $40.67
Resistance Level $18.45 N/A
Average True Range (ATR) 0.44 2.39
MACD 0.10 1.09
Stochastic Oscillator 58.33 97.96

Price Performance

Historical Comparison
PHI
KNSA

About PHI PLDT Inc. Sponsored ADR

PLDT Inc is a telecommunications and digital services provider. The group has three reportable operating segments: Wireless, Fixed Line, and Others. Maximum revenue is generated from its Fixed Line segment, which offers fixed line telecommunications services, servicing retail, corporate, and small and medium-sized enterprises clients. The Fixed Line business segment offers data, voice, and miscellaneous services. It also offers secure data centers, multi-cloud, cybersecurity, data, and artificial intelligence (AI) solutions through different subsidiaries. The Wireless segment generates revenue by offering access to mobile internet via smartphones, mobile broadband using pocket WiFi, or home WiFi using fixed wireless broadband devices. Geographically, the group operates in the Philippines.

About KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.

Share on Social Networks: